News Release 2008
-
- December 24, 2008
- Approval for an additional regimen and dose of Pentasa®for the treatment of ulcerative colitis in its active phase
-
- October 1, 2008
- Launch of Ulcerative Colitis and Crohn's Disease Therapeutic Agent Pentasa Tablets 500
-
- September 30, 2008
- Discontinuation of Commercialization of Gatiflo(gatifloxacin) Tablets, a broad-spectrum antibacterial agent, in Japan
-
- August 20, 2008
- Results of Overseas Clinical Studies for KRP-104, anti-diabetes agent
-
- April 22, 2008
- Execution of License Agreement on Flutiform, an Anti-asthmatic Treatment, in Japan
-
- April 18, 2008
- Launch of KIPRES Tablets 5mg
-
- March 3, 2008
- Pentasa Tablets 250 Received Approvals For Additional Pediatric Indication
-
- February 21, 2008
- Results of Analysis of the OASIS Study,a Large-Scale Health-Related QOL Study in Patients with Chronic Cerebral Infarction
-
- January 30, 2008
- Execution of an Exclusive Patent License and Collaborative Research and Development Agreement with Merck & Co.,Inc. in the Field of Infectious Diseases
-
- January 25, 2008
- KIPRES Received Approvals for Additional Indication to Relieve Symptoms of Allergic Rhinitis
